Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Semaglutide (Wegovy) was tested in clinical trials and was found to help people lose an average of 21% of their starting weight after 72 weeks on the 7.2mg maintenance dose
Using the Naranjo scale, 33 cases (84.6%) were deemed to have a probable causal relationship between GLP-1 RAs and AP, while 4 cases (10.3%) were classified as possible
Coverage will likely remain uneven across states for the foreseeable future
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which gives it a slightly different mechanism of action than semaglutide's single-target approach
Kidney problems: In rare cases, kidney problems can occur, especially if you experience severe vomiting or diarrhea, leading to dehydration
